A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).
Identifieur interne : 000704 ( Main/Exploration ); précédent : 000703; suivant : 000705A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).
Auteurs : Shiona K. Glass [Canada] ; David L. Pearl ; Scott A. Mcewen ; Rita FinleySource :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2010.
Descripteurs français
- KwdFr :
- Antibactériens (usage thérapeutique), Canada (MeSH), Ciprofloxacine (usage thérapeutique), Facteurs de risque (MeSH), Facteurs socioéconomiques (MeSH), Fluoroquinolones (usage thérapeutique), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Humains (MeSH), Infections de l'appareil respiratoire (traitement médicamenteux), Lévofloxacine (MeSH), Ofloxacine (usage thérapeutique), Utilisation médicament (statistiques et données numériques).
- MESH :
- statistiques et données numériques : Utilisation médicament.
- traitement médicamenteux : Grippe humaine, Infections de l'appareil respiratoire.
- usage thérapeutique : Antibactériens, Ciprofloxacine, Fluoroquinolones, Ofloxacine.
- épidémiologie : Grippe humaine.
- Canada, Facteurs de risque, Facteurs socioéconomiques, Humains, Lévofloxacine.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Anti-Bacterial Agents (therapeutic use), Canada (MeSH), Ciprofloxacin (therapeutic use), Drug Utilization (statistics & numerical data), Fluoroquinolones (therapeutic use), Humans (MeSH), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Levofloxacin (MeSH), Ofloxacin (therapeutic use), Respiratory Tract Infections (drug therapy), Risk Factors (MeSH), Socioeconomic Factors (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Ciprofloxacin, Fluoroquinolones, Ofloxacin.
- geographic : Canada, Levofloxacin.
- drug therapy : Influenza, Human, Respiratory Tract Infections.
- epidemiology : Influenza, Human.
- statistics & numerical data : Drug Utilization.
- Humans, Risk Factors, Socioeconomic Factors.
Abstract
OBJECTIVES
To assess potential risk factors among socioeconomic variables and the rate of influenza for the use of different fluoroquinolone antimicrobials in Canada, and to evaluate modelling fluoroquinolone-use data by two different outcome measures.
METHODS
Fluoroquinolone use was described monthly from 2000 to 2006 by two outcome measurements: defined daily doses and prescription counts. Multivariable linear and negative binomial models were produced with socioeconomic and influenza rate data.
RESULTS
Significant socioeconomic predictors varied among the individual fluoroquinolone models, which may reflect the range of infections that are treated with fluoroquinolones. However, socioeconomic variables within the ciprofloxacin and levofloxacin models were similar, and indicated that use was highest in advantaged populations, depending on the measures being assessed. The rate of influenza was a significant predictor within models describing levofloxacin use and the defined daily dose model for ciprofloxacin use, after accounting for season. Influenza significantly interacted with the education variable in the levofloxacin defined daily dose model.
CONCLUSIONS
Significant associations between levofloxacin use and influenza rates, after accounting for season, may suggest that levofloxacin was used to treat secondary bacterial infections or was prescribed inappropriately for seasonal viral respiratory tract infections. Yearly patterns of ciprofloxacin use show that prescribing practices changed; more ciprofloxacin prescriptions were dispensed towards the end of the study period, but for smaller doses or shorter treatment times. Associations with socioeconomic variables suggest that the fluoroquinolones ciprofloxacin and levofloxacin were more likely to be used in advantaged populations, probably due to the high cost of fluoroquinolone antimicrobials in comparison to the penicillin and macrolide groups.
DOI: 10.1093/jac/dkq225
PubMed: 20576640
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).</title><author><name sortKey="Glass, Shiona K" sort="Glass, Shiona K" uniqKey="Glass S" first="Shiona K" last="Glass">Shiona K. Glass</name><affiliation wicri:level="1"><nlm:affiliation>Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada. sglass@uoguelph.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Population Medicine, University of Guelph, Guelph, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Pearl, David L" sort="Pearl, David L" uniqKey="Pearl D" first="David L" last="Pearl">David L. Pearl</name></author><author><name sortKey="Mcewen, Scott A" sort="Mcewen, Scott A" uniqKey="Mcewen S" first="Scott A" last="Mcewen">Scott A. Mcewen</name></author><author><name sortKey="Finley, Rita" sort="Finley, Rita" uniqKey="Finley R" first="Rita" last="Finley">Rita Finley</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20576640</idno><idno type="pmid">20576640</idno><idno type="doi">10.1093/jac/dkq225</idno><idno type="wicri:Area/Main/Corpus">000636</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000636</idno><idno type="wicri:Area/Main/Curation">000636</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000636</idno><idno type="wicri:Area/Main/Exploration">000636</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).</title><author><name sortKey="Glass, Shiona K" sort="Glass, Shiona K" uniqKey="Glass S" first="Shiona K" last="Glass">Shiona K. Glass</name><affiliation wicri:level="1"><nlm:affiliation>Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada. sglass@uoguelph.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Population Medicine, University of Guelph, Guelph, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Pearl, David L" sort="Pearl, David L" uniqKey="Pearl D" first="David L" last="Pearl">David L. Pearl</name></author><author><name sortKey="Mcewen, Scott A" sort="Mcewen, Scott A" uniqKey="Mcewen S" first="Scott A" last="Mcewen">Scott A. Mcewen</name></author><author><name sortKey="Finley, Rita" sort="Finley, Rita" uniqKey="Finley R" first="Rita" last="Finley">Rita Finley</name></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term><term>Canada (MeSH)</term><term>Ciprofloxacin (therapeutic use)</term><term>Drug Utilization (statistics & numerical data)</term><term>Fluoroquinolones (therapeutic use)</term><term>Humans (MeSH)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Levofloxacin (MeSH)</term><term>Ofloxacin (therapeutic use)</term><term>Respiratory Tract Infections (drug therapy)</term><term>Risk Factors (MeSH)</term><term>Socioeconomic Factors (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antibactériens (usage thérapeutique)</term><term>Canada (MeSH)</term><term>Ciprofloxacine (usage thérapeutique)</term><term>Facteurs de risque (MeSH)</term><term>Facteurs socioéconomiques (MeSH)</term><term>Fluoroquinolones (usage thérapeutique)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Infections de l'appareil respiratoire (traitement médicamenteux)</term><term>Lévofloxacine (MeSH)</term><term>Ofloxacine (usage thérapeutique)</term><term>Utilisation médicament (statistiques et données numériques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Ciprofloxacin</term><term>Fluoroquinolones</term><term>Ofloxacin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term><term>Levofloxacin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Drug Utilization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Utilisation médicament</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Infections de l'appareil respiratoire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Ciprofloxacine</term><term>Fluoroquinolones</term><term>Ofloxacine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Risk Factors</term><term>Socioeconomic Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Canada</term><term>Facteurs de risque</term><term>Facteurs socioéconomiques</term><term>Humains</term><term>Lévofloxacine</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To assess potential risk factors among socioeconomic variables and the rate of influenza for the use of different fluoroquinolone antimicrobials in Canada, and to evaluate modelling fluoroquinolone-use data by two different outcome measures.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Fluoroquinolone use was described monthly from 2000 to 2006 by two outcome measurements: defined daily doses and prescription counts. Multivariable linear and negative binomial models were produced with socioeconomic and influenza rate data.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Significant socioeconomic predictors varied among the individual fluoroquinolone models, which may reflect the range of infections that are treated with fluoroquinolones. However, socioeconomic variables within the ciprofloxacin and levofloxacin models were similar, and indicated that use was highest in advantaged populations, depending on the measures being assessed. The rate of influenza was a significant predictor within models describing levofloxacin use and the defined daily dose model for ciprofloxacin use, after accounting for season. Influenza significantly interacted with the education variable in the levofloxacin defined daily dose model.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Significant associations between levofloxacin use and influenza rates, after accounting for season, may suggest that levofloxacin was used to treat secondary bacterial infections or was prescribed inappropriately for seasonal viral respiratory tract infections. Yearly patterns of ciprofloxacin use show that prescribing practices changed; more ciprofloxacin prescriptions were dispensed towards the end of the study period, but for smaller doses or shorter treatment times. Associations with socioeconomic variables suggest that the fluoroquinolones ciprofloxacin and levofloxacin were more likely to be used in advantaged populations, probably due to the high cost of fluoroquinolone antimicrobials in comparison to the penicillin and macrolide groups.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20576640</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation></Journal><ArticleTitle>A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).</ArticleTitle><Pagination><MedlinePgn>2019-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkq225</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess potential risk factors among socioeconomic variables and the rate of influenza for the use of different fluoroquinolone antimicrobials in Canada, and to evaluate modelling fluoroquinolone-use data by two different outcome measures.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fluoroquinolone use was described monthly from 2000 to 2006 by two outcome measurements: defined daily doses and prescription counts. Multivariable linear and negative binomial models were produced with socioeconomic and influenza rate data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significant socioeconomic predictors varied among the individual fluoroquinolone models, which may reflect the range of infections that are treated with fluoroquinolones. However, socioeconomic variables within the ciprofloxacin and levofloxacin models were similar, and indicated that use was highest in advantaged populations, depending on the measures being assessed. The rate of influenza was a significant predictor within models describing levofloxacin use and the defined daily dose model for ciprofloxacin use, after accounting for season. Influenza significantly interacted with the education variable in the levofloxacin defined daily dose model.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Significant associations between levofloxacin use and influenza rates, after accounting for season, may suggest that levofloxacin was used to treat secondary bacterial infections or was prescribed inappropriately for seasonal viral respiratory tract infections. Yearly patterns of ciprofloxacin use show that prescribing practices changed; more ciprofloxacin prescriptions were dispensed towards the end of the study period, but for smaller doses or shorter treatment times. Associations with socioeconomic variables suggest that the fluoroquinolones ciprofloxacin and levofloxacin were more likely to be used in advantaged populations, probably due to the high cost of fluoroquinolone antimicrobials in comparison to the penicillin and macrolide groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Shiona K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada. sglass@uoguelph.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearl</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>McEwen</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Finley</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>5E8K9I0O4U</RegistryNumber><NameOfSubstance UI="D002939">Ciprofloxacin</NameOfSubstance></Chemical><Chemical><RegistryNumber>6GNT3Y5LMF</RegistryNumber><NameOfSubstance UI="D064704">Levofloxacin</NameOfSubstance></Chemical><Chemical><RegistryNumber>A4P49JAZ9H</RegistryNumber><NameOfSubstance UI="D015242">Ofloxacin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002939" MajorTopicYN="N">Ciprofloxacin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024841" MajorTopicYN="N">Fluoroquinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064704" MajorTopicYN="N">Levofloxacin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015242" MajorTopicYN="N">Ofloxacin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20576640</ArticleId><ArticleId IdType="pii">dkq225</ArticleId><ArticleId IdType="doi">10.1093/jac/dkq225</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Finley, Rita" sort="Finley, Rita" uniqKey="Finley R" first="Rita" last="Finley">Rita Finley</name><name sortKey="Mcewen, Scott A" sort="Mcewen, Scott A" uniqKey="Mcewen S" first="Scott A" last="Mcewen">Scott A. Mcewen</name><name sortKey="Pearl, David L" sort="Pearl, David L" uniqKey="Pearl D" first="David L" last="Pearl">David L. Pearl</name></noCountry><country name="Canada"><noRegion><name sortKey="Glass, Shiona K" sort="Glass, Shiona K" uniqKey="Glass S" first="Shiona K" last="Glass">Shiona K. Glass</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000704 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000704 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20576640
|texte= A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20576640" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |